Evaluation of &lt;b&gt;&lt;i&gt;CYP17A1&lt;/i&gt;&lt;/b&gt; and &lt;b&gt;&lt;i&gt;LEP&lt;/i&gt;&lt;/b&gt; Gene Polymorphisms in Breast Cancer

Karakuş, Nevin; Kara, Nurten; Ulusoy, Ali Naki; Özaslan, Cihangir; Tural, Sengul; Okan, İsmail

doi:10.1159/000438940

Cited by 10 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final 27 studies included 9516 subjects (4542 BC patients/4974 controls). The baseline characteristics of the 21 incorporated studies regarding circulating leptin concentration in this meta-analysis are displayed in Table I [11, 12, 14, 17, 23–39], and the basic characteristics of the 7 included studies for G-2548A gene polymorphism are shown in Table II [15–19, 40, 41]. All the included studies had a case-control design and a clear diagnostic method for BC.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association between circulating leptin concentration and G-2548A gene polymorphism in patients with breast cancer: a meta-analysis

Hao

Zhang

Zhou

et al. 2019

aoms

View full text Add to dashboard Cite

IntroductionThe aim of this meta-analysis was to summarize the evidence on the serum/plasma leptin concentrations in breast cancer (BC) patients, as well as the associations between leptin G-2548A gene polymorphisms and susceptibility to BC.Material and methodsPotentially relevant studies about serum/plasma leptin levels and leptin G-2548A gene polymorphism were selected using the electronic databases PubMed, EMBASE and The Cochrane Library (from January 1 1995 to Jun 30 2017, no language restrictions). The potential sources of heterogeneity were assessed by the Q statistic and quantified using I2; publication bias was qualitatively assessed by funnel plot and quantitatively assessed by Egger’s linear regression test.ResultsA total of 1141 articles were retrieved after database searches, and 27 studies with 9516 subjects (4542 BC patients/4974 controls) were finally included. The results indicated that BC patients had significantly higher leptin levels compared with healthy controls (SMD = 1.65, 95% CI: 1.21–2.09, p < 0.001), but there was no association between leptin G-2548A polymorphism and BC (OR = 1.05, 95% CI: 0.80–1.39, p = 0.722). Subgroup analyses demonstrated increased leptin levels in BC patients of different region, race, body mass index and waist circumference.ConclusionsOur results revealed a significantly higher leptin level in BC patients than in healthy controls, but no association between leptin G-2548A polymorphism and BC susceptibility was found.

show abstract

Section: Resultsmentioning

confidence: 99%

“…It was found that subjects carrying the leptin G-2548A (rs7799039) gene polymorphism had an increased risk for breast carcinoma [15, 16]. Nevertheless, some studies reported that leptin G-2548A gene polymorphism was not associated with susceptibility to BC [17–19].…”

Section: Introductionmentioning

confidence: 99%

Association between circulating leptin concentration and G-2548A gene polymorphism in patients with breast cancer: a meta-analysis

Hao

Zhang

Zhou

et al. 2019

aoms

View full text Add to dashboard Cite

show abstract

“…Among them, 19 were conducted in Caucasians,26–44 eight performed in Asians,21,45–50,54 and four were in mixed populations 51–53. Nine were population-based,27,28,30,33,37,38,43,44,50 and 22 case–control were hospital-based studies 21,26,29,31,32,34–36,39–42,45–49,51–54. Of all the eligible studies, 11 focused on breast cancer,33,37–40,44,48,49,51,53 four focused on colorectal cancer (CRC),31,32,41,52 three focused on prostate cancer (PC),26,30,34 and 13 focused on other cancers 21,27–29,35,36,42,43,45–47,50,54.…”

Section: Resultsmentioning

confidence: 99%

<p>Leptin rs7799039 (G2548A) polymorphism is associated with cancer risk: a meta-analysis involving 25,799 subjects</p>

Tang

Kang

Liu

et al. 2019

OTT

View full text Add to dashboard Cite

Background: Leptin (LEP) is a human analogous form of the mouse obese gene and plays a critical role in energy expenditure as well as the progression of carcinogenesis. Many studies exploring the relationship between the LEP rs7799039 (G2548A) polymorphism and cancer risk have observed controversial results. To extensively evaluate this potential association, we conducted this meta-analysis. Methods: All eligible studies published up to August 2018 on the relationship between the LEP rs7799039 G>A polymorphism and cancer risk were obtained by searching PubMed, EMBASE, and the China Biology Medicine databases. The association of LEP rs7799039 G>A polymorphism with cancer risk was evaluated by crude ORs together with their 95% CI's. Results: Thirty-one case–control studies involving 25,799 subjects were included for meta-analysis. We identify a significant correlation with an overall cancer risk when these eligible case–control studies were pooled for analysis: for AA vs GG: an OR = 1.22, 95% CI = 1.01–1.48, P = 0.042 and for AA/GA vs GG: an OR = 1.16, 95% CI = 1.02–1.33, P = 0.026. A significant association was also detected in Asians, prostate cancer, other cancers, and hematopoietic malignancy subgroups. Sensitivity analysis was conducted by deleting an individual study in turn and calculation of the pooled ORs and CIs of the remainders. The results of sensitivity analyses indicated that no eligible study influenced the pooled ORs and CIs materially. Begg’s and Egger’s tests revealed that there was no evidence of publication bias. Conclusion: In conclusion, our study suggests that the LEP rs7799039 G>A polymorphism might contribute to the development of cancer. In order to further verify or refute our findings, large and well-designed epidemiological studies are needed.

show abstract

“…A number of previous studies demonstrated a critical role for molecular biomarkers in tumor pathogenesis (24)(25)(26). In OS, specific prognostic biomarkers have additionally been identified.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of miR‑136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma

Chu

Wang

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common bone tumor in children and young adults, and is an aggressive tumor with poor prognosis. MicroRNAs (miRNAs) are aberrantly expressed in various types of cancer, and contribute to cancer tumorigenesis and progression. In the present study, the potential prognostic value and biological function of miRNA-136 (miR-136) in OS was investigated. Reverse transcription-quantitative polymerase chain reaction analysis was used to evaluate the expression of miR-136 in OS tissues and cell lines. Kaplan-Meier survival analysis and Cox regression analysis were conducted to investigate the prognostic significance of miR-136. Various in vitro cell based assays were used to evaluate the effects of miR-136 on the biological behavior of OS cells. A luciferase assay was performed to determine the key miR-136 targets associated with OS. The expression of miR-136 was significantly downregulated in osteosarcoma tissues and cells compared with the normal controls (all P<0.05). Decreased miR-136 expression was significantly associated with Enneking staging (P=0.030) and distant metastasis (P=0.016). Decreased miR-136 expression in patients was associated with shorter overall survival compared with patients with increased expression levels (log-rank test; P<0.05). The expression of miR-136 was indicated as an independent prognostic factor for the patients (hazard ratio= 0.496; 95% confidence interval=0.250-0.987; P=0.046). MTT, transwell and Matrigel assays demonstrated that upregulation of miR-136 decreased proliferation, migration and invasion of OS cells. Bioinformatics and luciferase assays demonstrated that migration and invasion enhancer 1 (MIEN1) is a direct target of miR-136. Together, the results suggested that miR-136 functions as a tumor suppressor gene to regulate proliferation, migration and invasion of OS cells. MIEN1 was a potential target of miR-136. Additionally, miR-136 may serve as a prognostic biomarker for OS.

show abstract

Evaluation of <b><i>CYP17A1</i></b> and <b><i>LEP</i></b> Gene Polymorphisms in Breast Cancer

Cited by 10 publications

References 24 publications

Association between circulating leptin concentration and G-2548A gene polymorphism in patients with breast cancer: a meta-analysis

Association between circulating leptin concentration and G-2548A gene polymorphism in patients with breast cancer: a meta-analysis

<p>Leptin rs7799039 (G2548A) polymorphism is associated with cancer risk: a meta-analysis involving 25,799 subjects</p>

Downregulation of miR‑136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma

Contact Info

Product

Resources

About